A phase II efficacy and tolerability study of RTA 744 in breast cancer patients with progression of previously irradiated brain metastases.
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2014
At a glance
- Drugs Berubicin (Primary)
- Indications Breast cancer; Cancer metastases
- Focus Therapeutic Use
- Sponsors Reata Pharmaceuticals
- 04 Jun 2012 Actual patient number is 14 according to ClinicalTrials.gov.
- 04 Jun 2012 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.
- 17 Feb 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.